Literature DB >> 12081993

Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy.

Carolyn Y Ho1, Nancy K Sweitzer, Barbara McDonough, Barry J Maron, Susan A Casey, J G Seidman, Christine E Seidman, Scott D Solomon.   

Abstract

BACKGROUND: Unexplained left ventricular hypertrophy (LVH) is considered diagnostic of hypertrophic cardiomyopathy (HCM) but fails to identify all genetically affected individuals. Altered diastolic function has been hypothesized to represent an earlier manifestation of HCM before the development of LVH; however, data regarding the clinical utility of imaging techniques that assess this parameter are limited. METHODS AND
RESULTS: Echocardiographic studies including Doppler tissue imaging (DTI) were performed in a genotyped HCM population with beta-myosin heavy chain (beta -MHC) mutations. Genotype (+) individuals with LVH (G+/LVH+; n=18) and genotype (+) individuals without LVH (G+/LVH-; n=18) were compared with normal control subjects (n=36). Left ventricular ejection fraction (EF) was significantly higher in both genotype (+) groups (75+/-5% and 71+/-6%, respectively, versus 64+/- 5% in control subjects; P<0.0001). Mean early diastolic myocardial velocities (Ea) were significantly lower in both genotype (+) subgroups, irrespective of LVH (P<0.02). However, there was substantial overlap in Ea velocities between the G+/LVH- and control groups. An Ea velocity of < or =13.5 cm/s had 86% specificity and 75% sensitivity for identifying genotype-positive subjects. The combination of EF > or =68% and Ea velocity <15 cm/s was 100% specific and 44% sensitive in predicting affected genotype.
CONCLUSIONS: Abnormalities of diastolic function assessed by Doppler tissue imaging precede the development of LVH in individuals with HCM caused by beta -MHC mutations. Although Ea velocity alone was not sufficiently sensitive as a sole diagnostic criterion, the combination of Ea velocity and EF was highly predictive of affected genotype in individuals without overt manifestations of HCM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12081993     DOI: 10.1161/01.cir.0000019070.70491.6d

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  120 in total

Review 1.  The role of magnetic resonance imaging in hypertrophic cardiomyopathy.

Authors:  Edward T D Hoey; Mohamed Elassaly; Arul Ganeshan; Richard W Watkin; Helen Simpson
Journal:  Quant Imaging Med Surg       Date:  2014-10

2.  To screen or not is not the question--it is when and how to screen.

Authors:  A J Marian; R Roberts
Journal:  Circulation       Date:  2003-05-06       Impact factor: 29.690

3.  Can an energy-deficient heart grow bigger and stronger?

Authors:  Robert Roberts; Ali J Marian
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

4.  Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease.

Authors:  Sherif F Nagueh; Judy McFalls; Denise Meyer; Rita Hill; William A Zoghbi; James W Tam; Miguel A Quiñones; Robert Roberts; A J Marian
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

Review 5.  Utility of echocardiography in the evaluation of individuals with cardiomyopathy.

Authors:  Malissa J Wood; Michael H Picard
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

6.  MRI of nonischemic cardiomyopathy.

Authors:  David A Bluemke
Journal:  AJR Am J Roentgenol       Date:  2010-10       Impact factor: 3.959

Review 7.  Hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho
Journal:  Heart Fail Clin       Date:  2010-04       Impact factor: 3.179

Review 8.  Mechanical and energetic consequences of HCM-causing mutations.

Authors:  Cecilia Ferrantini; Alexandra Belus; Nicoletta Piroddi; Beatrice Scellini; Chiara Tesi; Corrado Poggesi
Journal:  J Cardiovasc Transl Res       Date:  2009-10-09       Impact factor: 4.132

9.  The tale of the three sisters.

Authors:  J Liu; M J Cramer; G E Leenders; J Zhao; P A Doevendans; P G Melman
Journal:  Neth Heart J       Date:  2010-11       Impact factor: 2.380

Review 10.  Pseudophosphorylation of cardiac myosin regulatory light chain: a promising new tool for treatment of cardiomyopathy.

Authors:  Sunil Yadav; Danuta Szczesna-Cordary
Journal:  Biophys Rev       Date:  2017-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.